PHARMACOVIGILANCE: AN OVERVIEW

Ashish Chauhan; Manoj Goyal

Ashish Chauhan I.P.S.college of Pharmacy,Gwalior.
Manoj Goyal I.P.S.college of Pharmacy,Gwalior.

Abstract

Pharmacovigilance is an important and integral part of clinical research. Pharmacovigilance is “defined as the pharmacological science relating to the detection, assessment, understanding and prevention of adverse effects, particularly long term and short term adverse effects of medicines. This addresses what exactly is pharmacovigilance? What do we know of its benefits and risks, challenges and the future hold for pharmacovigilance in Indian medicine. Here the main focus on the aims and role of pharmacovigilance in medicines regulation and their Partners. This article describes and discusses the National programme of pharmacovigilance and centre in India. Their role in collecting the reports ADRs of medicines. Further effectiveness and risk assessments of therapies are been discussed. The important role played by health care professional, pharmaceutical industries, media, and programmes carried by WHO. Finally the conclusion describes the major challenges and achievements for the future pharmacovigilance programme.

Keywords: Pharmacovigillance, National Programme

References

1.Pipasha B, Arun KB. Setting standards for proactive pharmacovigilance in India : The way forward. Indian J pharmacol. 2007;39(3): 124-128.
2.Kumanan R, Sudha S, Vijayashre P, Charumath S, Gowridevi KC, Mahesh M. Imperative Approach on pharmacovigilance in Indian systems of medicines. International journal of pharma sciences and Research (ijpsr). 2010;1(9): 378-390.
3.Deepa A. Pharmacovigilance obligations of the pharmaceutical companies in India. Indian J pharmacol. 2008;40: S13-S16.
4.WHO, Pharmacovigilance: ensuring the safe use of medicines, Geneva: WHO 2004.
5.WHO, Safety of medicines in public health programmes : pharmacovigilance an essential tool,WHO,2006. 6.Yves S. Pharmacovigilance for pharmacist, Johnson &Johnson (2006).
7.Edwards IR. The accelerating need for pharmacovigilance. Journal of the Royal college of Physicians. 2000;34: 48-51.
8.Lazarou J. Incidence of ADR in hospitalized patients: A meta analysis of prospective studies. Journal of the American medical association. 1998; 279:1000- 1008
9.Meyboom RHB, Egberts ACG, Gribnau FWJ, Hekster YA. Drug Safety: Pharmacovigilance in perspective. 1999; 21(6): 429-447.
10.Mary R. couper and shanthi pal :Quality assurance and safety of medicines ,WHO, Geneva (2008). 11.Sten O. Pharmacovigilance training with focus on India. Indian J pharmacol 2008; 40: S28-S30 12.Talbot JCC, Nilsson BS. Pharmacovigilance in the Pharmaceutical industry. British Journal of Pharmacology. 1998; 45:427-431.
13. WHO guidelines on safety monitoring of herbal medicines in pharmacovigilance systems, World Health Organization, Geneva ( 2004).
14. Rahman SZ, Singhal KC. Problems in pharmacovigilance of medicinal products of herbal origin and means to minimize them, Uppsala Reports, WHO Collaborating Center for ADR monitoring, Uppsala Monitoring Centre, Sweden, (2002): 1-4.
15. Edwards R. The future of pharmacovigilance: a personal view. Eur J Clin Pharmacol. 2008; 64:173-181.